A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus

•PF-06291874 was generally well tolerated and had a low risk for hypoglycemia.•PF-06291874 resulted in robust reductions in plasma glucose levels in T2DM patients.•PF-06291874 had minimal effects on plasma LDL-C at clinically relevant doses.